Results of the study presented at San Antonio's Breast Cancer Symposium 2018
The Immunotherapy Laboratory INmune Bio, Inc., which is developing treatment for reprogramming the innate immune system, today announced that the leading drug candidate for treatment-resistant cancer, INB03 ™, successfully inhibits proliferation of tumor growth in preclinical models of breast cancer , resistant to treatment with trastuzumab. The study was conducted by Ms Roxana Schillaci, a researcher at the Institute of Biology and Experimental Medicine (IBYME-CONICET). Dr. Shilaci presented the data during a poster presentation at San Antonio's Breast Cancer Symposium in San Antonio, Texas, on December 8th.
In the United States, one of eight women will develop breast cancer with invasive ductal carcinoma (IDC) in their lives. Two of these eight will have positive breast cancer with human epidermal growth factor 2 (HER2), which is treated with trastuzumab – an immunotherapy targeted to HER2. Primary or secondary resistance to treatment is a significant clinical problem that occurs in half of patients receiving trastuzumab for the treatment of their HER2 positive breast cancer.
"Today, the definition of trastuzumab resistant breast cancer is the progression of breast cancer while the patient is on trastuzumab treatment," said Dr. Shilaci. "Our work shows that mucin 4 (MUC4) proteins that block trastuzumab from binding to HER2 receptors can be used as biomarkers to predict resistance to treatment." Furthermore, data suggest that resistance to trastuzumab can be reversed by elimination of soluble tumor necrosis factor (sTNF) in the tumor microenvironment ".
Dr. Shilachi's work has shown that expression of MUC4 protein on cancer cells predicts resistance to trastuzumab. Expression of MUC4 is caused by sTNF. Dr. Schillaci used INB03 to inhibit sTNF in mice to reduce MUC4 expression and reverse resistance to trastuzumab. In further work, Dr. Shihalchi's team demonstrated that women resistant to trastuzumab expressed MUC4 on the tumor, while trastuzumab-susceptible patients did not.
"The results of this study show the possible solution to a continuing problem in the treatment of women with HER2 positive breast cancer – predicting and treating resistance to trastuzumab," said RJ Tesi, MD, CEO and co-founder of INmune Bio. "If this work is confirmed in the clinic, adding sTNF-targeted therapy, such as INB03, may improve treatment options for a group of women who previously did not benefit from trastuzumab immunotherapy."
INmune Bio initiated a clinical trial at INB03 on May 23rd, 23rd. The other drug candidate, INKmune ™, will enter clinical trials in early 2019.
About INmune Bio, Inc.
INmune Bio, Inc. is a private clinical biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two platforms for products that reinterpret the patient's innate immune response to cancer, INKmune and INB03. INKmune is a natural killer (NK) cell therapy that provokes the patient's NK cells to attack developing disease. INB03 inhibits mycelial suppressor cells (MDSC), which often cause resistance to immunotherapy as anti-PD1 control point inhibitors. INmune Bio's product platforms aim for residual disease and use the approach to a precise medical approach to treat a wide variety of hematological malignancies and solid tumors. To learn more, please visit www.inmunebio.com.
© 2018 GlobeNewswire, Inc. All rights reserved.
SOURCE: INmune Bio, Inc.